Related Experiment Video
Updated: Aug 13, 2026
09:07
Detecting the Ligand-binding Domain Dimerization Activity of Estrogen Receptor Alpha Using the Mammalian Two-Hybrid Assay
Published on: December 19, 2018
Muscarinic cholinergic modulation of hypothalamic estrogen binding sites
1Department of Psychology, University of California, Riverside 92521.
Brain Research
|March 8, 1988
Summary
Cholinergic drugs like bethanechol can increase hypothalamic estrogen receptors in female rats, but not males. This suggests neurotransmitter effects on brain estrogen receptors are sex-specific.
Area of Science:
- Neuroendocrinology
- Neuropharmacology
- Molecular Endocrinology
Background:
- Previous studies linked dopaminergic and noradrenergic systems to hypothalamic estrogen receptor regulation.
- This suggested a role for catecholamines in controlling brain estrogen receptors.
Purpose of the Study:
- To investigate if neurotransmitter systems other than catecholaminergic ones affect brain estrogen receptors.
- To determine the impact of muscarinic cholinergic agents on hypothalamic estradiol binding.
Main Methods:
- Administered bethanechol, a muscarinic cholinergic agonist, to ovariectomized female rats.
- Assessed changes in cytosolic hypothalamic [3H]estradiol binding sites.
- Used atropine sulfate, a muscarinic antagonist, to block bethanechol's effects.
- Compared effects in castrated male rats.
Main Results:
- Bethanechol significantly increased hypothalamic estradiol binding sites by up to 38% in females.
- Atropine sulfate pretreatment abolished the bethanechol-induced increase.
- Bethanechol had no significant effect on estradiol binding sites in male rats.
Conclusions:
- Pharmacological modulation of hypothalamic estrogen receptors is not exclusive to catecholaminergic systems.
- Muscarinic cholinergic pathways can influence estrogen receptor concentrations.
- These effects appear to be sex-specific, highlighting differential regulation in males and females.
Related Concept Videos
01:25Cholinergic Receptors: Muscarinic
The pharmacological actions of acetylcholine are elicited via its binding to two families of cholinergic receptors or cholinoceptors, namely, muscarinic and nicotinic receptors. Muscarinic receptors are G protein-coupled receptors and have five subtypes, M1–M5. All mAChR subtypes are activated by acetylcholine and blocked by the antagonist, atropine.
The subtypes M1, M3, and M5 couple with the Gq subunit and activate the phospholipase C (PLC) activity, mobilizing intracellular Ca2+. Activation...
The subtypes M1, M3, and M5 couple with the Gq subunit and activate the phospholipase C (PLC) activity, mobilizing intracellular Ca2+. Activation...
01:22Direct-Acting Cholinergic Agonists: Chemistry and Structure-Activity Relationship
Cholinergic agonists or cholinomimetics mimic the action of acetylcholine to stimulate the parasympathetic nervous system. They are categorized into direct-acting and indirect-acting agents. The direct-acting cholinergic drugs induce the parasympathetic response by directly binding to the muscarinic or nicotine receptors. In comparison, the indirect-acting cholinergic drugs prevent acetylcholine hydrolysis, indirectly contributing to the extended parasympathetic response.
The direct-acting...
The direct-acting...
01:31Direct-Acting Cholinergic Agonists: Pharmacokinetics
Direct-acting cholinergic agonists, such as synthetic choline esters and naturally occurring alkaloids, exert their effects by enhancing the actions of acetylcholine and stimulating the parasympathetic nervous system. Synthetic choline esters share structural similarities with acetylcholine. For example, they have a positively charged quaternary ammonium or onium group, contributing to their hydrophilic characteristics. As a result, they are poorly absorbed in the body through oral...
00:59Direct-Acting Cholinergic Agonists: Pharmacological Actions
Direct-acting cholinergic agonists exert their pharmacological actions by mimicking the effects of acetylcholine on postsynaptic muscarinic receptors to generate parasympathetic responses. These agents elicit a range of physiological responses, including cardiovascular effects. For example, activation of muscarinic receptors induces bradycardia, decreased cardiac output, reduced peripheral resistance, and consequent hypotension. In the eye, stimulation of M3 receptors leads to smooth muscle...
01:11Direct-Acting Cholinergic Agonists: Therapeutic Uses
Direct-acting cholinergic agonists have many therapeutic uses in various medical fields. Choline esters, including acetylcholine, have limited clinical utility due to their non-selectivity and short duration of action. Still, acetylcholine and carbachol are applied topically during ophthalmologic surgery to induce miosis. Pilocarpine, a muscarinic and ganglionic stimulator, effectively treats open-angle glaucoma and alleviates xerostomia and dry mouth caused by radiotherapy or Sjögren syndrome.
01:28Cholinergic Antagonists: Pharmacological Actions
Antimuscarinic drugs block muscarinic receptors in multiple systems, including the gut, eye, smooth muscles, respiratory tract, cardiovascular, and central nervous systems. They produce similar effects with varying selectivity depending on the specific agent and tissue. Here are the key pharmacological actions of antimuscarinics:
Gastrointestinal Effects: Antimuscarinics reduce gut contractions, increase gastric emptying, and slow intestinal transit. They partly inhibit gastric acid secretion...
Gastrointestinal Effects: Antimuscarinics reduce gut contractions, increase gastric emptying, and slow intestinal transit. They partly inhibit gastric acid secretion...